Connect your AI

Evommune EVMN Current liabilities

Current liabilities at other companies

Rocket Lab USA, Inc.RKLB

-$2.94M+20.5%

Xcel EnergyXEL

$110M+279%

CSXCSX

-$36M-500%

S&P GlobalSPGI

-$29M+50.0%

Bloom EnergyBE

-$1.37M+96.1%

L3Harris TechnologiesLHX

-$15M-236%

Other financials

Income statement

Revenue$1.6M+3.5%

Gross profit$961.1K+10.9%

Operating income-$682.8K-2,027%

Net income-$7.0M-5,414%

EPS (diluted)-$0.36-1,700%

Balance sheet

Cash & equivalents$1.1M+401%

Total debt$2.0M—

Total equity-$4.5M-3,048%

Total assets$7.2M—

Cash flow

Operating cash flow-$424.6K-341%

CapEx$1.0-99.8%

Free cash flow-$2.7M-4,996%

Valuation

Market cap$848.59M+39.5%

Enterprise value$849.52M—

P/S127.3×—

Profitability

Gross margin53.7%—

Operating margin-30.7%—

Net margin-90.1%—

Returns & leverage

Return on equity275.7%—

Debt / equity1.4×—

Current ratio1.2×—

Where this comes from

Reported directly by Evommune in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherCurrentLiabilities.

The official record: Evommune ’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about Evommune 's current liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Evommune 's current liabilities?: Evommune (EVMN) reported current liabilities of -$11.15K in Q1 2026.
How has Evommune 's current liabilities changed year-over-year?: Evommune 's current liabilities decreased by 57.8% year-over-year, from -$7.07K to -$11.15K.